RxDoctor Payments Data

Vera Garcia, MD

Family Medicine · Valdosta, GANPI 1154401107

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 132 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$633
  • AstraZeneca$429
  • Novo Nordisk$296
  • Lilly USA, LLC$209
  • Amgen$126
  • AbbVie$114
  • plus $756 from 18 others

What the payments were for

  • Food & beverage$2,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,564 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$59,993
Medicare patients
123
Services billed
1,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$112,869
JardianceEmpagliflozin107$99,868
EliquisApixaban102$80,950
FarxigaDapagliflozin Propanediol81$72,966
JanuviaSitagliptin Phosphate54$49,355
MounjaroTirzepatide36$38,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,021
RybelsusSemaglutide18$30,700
VraylarCariprazine Hcl19$30,009
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$26,323
LinzessLinaclotide40$25,320
Tresiba Flextouch U-200Insulin Degludec20$21,193
RexultiBrexpiprazole13$20,391
Combivent RespimatIpratropium/Albuterol Sulfate22$15,424
XareltoRivaroxaban24$14,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$296$143,569125 claims
Boehringer IngelheimJardiance, Combivent Respimat$72$115,292129 claims
AstraZenecaFarxiga, Breztri Aerosphere$429$99,289118 claims
PfizerEliquis$66$80,950102 claims
AbbVieVraylar, Linzess$114$55,33059 claims
Lilly USA, LLCMounjaro, Trulicity$209$53,31151 claims
GSKTrelegy Ellipta, Shingrix$633$37,26968 claims
Otsuka America Pharmaceutical, Inc.Rexulti$29$20,39113 claims
Johnson & JohnsonXarelto$20$14,80524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →